Aims: To examine the association between alcohol consumption and mental health during the COVID-19 pandemic. Methods: An anonymous online survey was distributed among US adults during May–August 2020 through social networks and ResearchMatch. We collected information on demographic, lifestyles and mental health symptoms including anxiety, depression, stress and post-traumatic stress disorder. Logistic regression models were used to examine the cross-sectional association between alcohol consumption and mental health symptoms. We also examined effect modification by race, age, gender, social support, financial insecurity and quarantine status. Results: The analytical sample consists of 3623 adults. Stable drinking habits and regular drinking behaviors were found to co-exist with better mental health status. Participants who increased their alcohol use had higher odds of developing mental health disorders than those who maintained their pre-pandemic drinking habits. Additionally, participants who engaged in binge drinking during the pandemic had higher odds of depression and stress than those who did not. The associations regarding increased drinking and binge drinking in relation to adverse mental health outcomes were stronger among females, racial minorities, and individuals with financial concerns, poor social support and restricted quarantine status than their counterparts. Conclusions: During the early stage of the COVID-19 pandemic, increased alcohol use and binge drinking are cross-sectionally associated with higher odds of mental health disorders, which highlighted the need for targeted intervention to address the mental health needs of individuals who have engaged in these behaviors, especially among females, minorities, those with insecurities or with restricted quarantine status.
30 July 2025 in British Journal of Clinical Pharmacology
Aims: Clinical guidelines for breast cancer management have evolved in the past decade. However, limited evidence exists regarding uptake of novel drug classes in management of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) in the USA and whether disparities exist by race and ethnicity. Methods: Using SEER‐Medicare databases, we identified 4404 women aged ≥66 years diagnosed with HR+ de novo MBC (dnMBC) between 2010 and 2019. Age‐standardized rates for receipt of first‐line treatment were calculated. Age‐adjusted rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using Poisson regression to compare rates among non‐Hispanic Black (NHB) and Hispanic patients with non‐Hispanic White (NHW) patients. Results: Among patients with HR+/human epidermal growth factor receptor 2‐negative (HER2−) dnMBC after 2015, 48.6% received first‐line treatment with aromatase inhibitors (AIs) and 22.8% with AIs plus cyclin‐dependent kinase (CDK) 4/6 inhibitors. Rates for AIs + CDK4/6 inhibitors increased (per 1000 person‐years: 262.2 in 2015; 452.8 in 2019). Compared with NHW, NHB (RR [95% CI%]: 0.87 [0.63–1.21]) and Hispanic patients (RR [95% CI%]: 0.74 [0.51–1.08]) were less likely to receive AIs + CDK4/6 inhibitors. For HR+/HER2+ dnMBC, 29.7% of patients received pertuzumab, 23.1% with AIs and 10.8% with AIs + trastuzumab. Rates for pertuzumab increased, while rates for trastuzumab monotherapy declined. Compared with NHW, NHB and Hispanic women were less likely to receive anti‐HER therapy (RR [95% CI]: 0.51 [0.35–0.73] and 0.58 [0.39–0.86]). Conclusion: There is a temporal increase in first‐line treatment with AIs + CDK4/6 inhibitors and pertuzumab in dnMBC in the USA but with significant disparities by race and ethnicity.
There is limited evidence on how reduced healthcare resource utilization during the COVID-19 pandemic has affected the detection of inflammatory and immunologic diseases. We aimed to describe the observed incidence rates (IRs) of asthma, atopic dermatitis (AD), and multiple sclerosis (MS) before, during, and after the pandemic. Individuals aged ≥6 years were identified in Optum’s de-identified Clinformatics ® Data Mart Database from 2018 to 2022 to make 20 season-based cohorts. Age- and sex-standardized IRs of asthma, AD, and MS were estimated. Incidence rate ratios (IRR) and 95% confidence intervals (CI) were calculated comparing IRs in seasonal cohorts in 2019–2022 to the corresponding timeframe in 2018. Compared to spring 2018, IRs of asthma, AD, and MS in spring 2020 decreased by 14% (IRR: 0.86, 95% CI: 0.84–0.87), 28% (IRR: 0.72, 95% CI: 0.69–0.75), and 23% (IRR: 0.77, 95% CI: 0.68–0.87), respectively. The observed incidence reduction was most profound in children (6–11 years) and adolescents (12–17 years), followed by senior adults (≥65 years). There was no sex difference. IRs returned to or exceeded pre-pandemic levels for AD and MS in summer 2020 and for asthma in spring 2021. COVID-19 led to an apparent decline in incidence for selected inflammatory and immunologic diseases, which was more pronounced for pediatric and senior populations. The observed decrease in incidence likely reflects delayed access to healthcare, resulting in unrecorded (but still occurring) diagnoses for those time periods. Future studies using data that encompass the pandemic period should exercise caution in the design of study and interpretation of incidence or prevalence data.